JP2022505146A5 - - Google Patents

Info

Publication number
JP2022505146A5
JP2022505146A5 JP2021521085A JP2021521085A JP2022505146A5 JP 2022505146 A5 JP2022505146 A5 JP 2022505146A5 JP 2021521085 A JP2021521085 A JP 2021521085A JP 2021521085 A JP2021521085 A JP 2021521085A JP 2022505146 A5 JP2022505146 A5 JP 2022505146A5
Authority
JP
Japan
Application number
JP2021521085A
Other languages
Japanese (ja)
Other versions
JPWO2020082065A5 (https=
JP7534291B2 (ja
JP2022505146A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/057195 external-priority patent/WO2020082065A1/en
Publication of JP2022505146A publication Critical patent/JP2022505146A/ja
Publication of JP2022505146A5 publication Critical patent/JP2022505146A5/ja
Publication of JPWO2020082065A5 publication Critical patent/JPWO2020082065A5/ja
Priority to JP2024075254A priority Critical patent/JP2024096347A/ja
Application granted granted Critical
Publication of JP7534291B2 publication Critical patent/JP7534291B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021521085A 2018-10-19 2019-10-21 9(11)-不飽和神経刺激性ステロイド及びそれらの使用方法 Active JP7534291B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024075254A JP2024096347A (ja) 2018-10-19 2024-05-07 9(11)-不飽和神経刺激性ステロイド及びそれらの使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748016P 2018-10-19 2018-10-19
US62/748,016 2018-10-19
PCT/US2019/057195 WO2020082065A1 (en) 2018-10-19 2019-10-21 9(11)-unsaturated neuroactive steroids and their methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024075254A Division JP2024096347A (ja) 2018-10-19 2024-05-07 9(11)-不飽和神経刺激性ステロイド及びそれらの使用方法

Publications (4)

Publication Number Publication Date
JP2022505146A JP2022505146A (ja) 2022-01-14
JP2022505146A5 true JP2022505146A5 (https=) 2022-10-31
JPWO2020082065A5 JPWO2020082065A5 (https=) 2022-10-31
JP7534291B2 JP7534291B2 (ja) 2024-08-14

Family

ID=68468867

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021521085A Active JP7534291B2 (ja) 2018-10-19 2019-10-21 9(11)-不飽和神経刺激性ステロイド及びそれらの使用方法
JP2024075254A Pending JP2024096347A (ja) 2018-10-19 2024-05-07 9(11)-不飽和神経刺激性ステロイド及びそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024075254A Pending JP2024096347A (ja) 2018-10-19 2024-05-07 9(11)-不飽和神経刺激性ステロイド及びそれらの使用方法

Country Status (13)

Country Link
US (2) US20210363175A1 (https=)
EP (2) EP3867261B1 (https=)
JP (2) JP7534291B2 (https=)
CN (1) CN113227114B (https=)
AR (1) AR116771A1 (https=)
AU (2) AU2019359899B2 (https=)
BR (1) BR112021007401A2 (https=)
CA (1) CA3116892A1 (https=)
DK (1) DK3867261T3 (https=)
ES (1) ES3039267T3 (https=)
MX (2) MX2021004452A (https=)
TW (1) TW202027754A (https=)
WO (1) WO2020082065A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス, インコーポレイテッド 19−ノルc3,3−ジ置換c21−n−ピラゾリルステロイドおよびその使用方法
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953429A (en) * 1970-12-17 1976-04-27 Glaxo Laboratories Limited Anaesthetic steroids of the androstance and pregnane series
DE2526373C2 (de) * 1975-06-11 1983-11-10 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden
JP2545522B2 (ja) * 1985-10-23 1996-10-23 アルコン・ラボラトーリーズ,インコーポレイテッド テトラヒドロ脈管形成抑制ステロイド
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US10577390B2 (en) * 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
MA45599A (fr) * 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
JP2022505146A5 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)